0000000000638200

AUTHOR

Teresa Amaral

showing 2 related works from this author

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

2016

The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified the training and development of YOs as a priority and has therefore established a comprehensive career development programme. This includes a leadership development programme to help identify and develop the future leaders in oncology. Well-trained and highly motivated future generations of multidisciplinary oncologists are essential to ensure the optimal evolution of the field of oncology with the ultimate goal of pro…

Oncologymedicine.medical_specialtyCancer ResearchReviewFellowshipExecutive boardMultidisciplinary approachInternal medicineJournal ArticleMedicine15061507Leadership developmentbusiness.industryLeadership ProgrammeGénéralitésESMOTraining and developmentYoung OncologistsOncologyESMO; Fellowship; Leadership Programme; Preceptorship; Young OncologistsPreceptorshipPortfoliobusinessCareer developmentESMO; Fellowship; Leadership Programme; Preceptorship; Young Oncologists; Cancer Research; Oncology
researchProduct

Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Im…

2021

Early tumor size reduction (TSR) has been explored as a prognostic factor for survival in patients with advanced melanoma in clinical trials. The purpose of this analysis is to validate, in a routine clinical milieu, the predictive capacity of TSR by 10% for overall survival (OS) and progression-free survival (PFS) and to compare its predictive performance with the RECIST 1.1 criteria.This retrospective study was approved by the local ethics committee. A total of 152 patients with both CT before immunotherapy initiation and at first response evaluation after immunotherapy initiation were included. Prior to statistical analysis, treatment response was trichotomized as follows: Complete respo…

Oncologymedicine.medical_specialtyContext (language use)030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProgression-free survivalProspective cohort studyMelanomaRetrospective Studiesbusiness.industryMelanomafungiRetrospective cohort studymedicine.diseaseClinical trialTreatment Outcome030220 oncology & carcinogenesisBiomarker (medicine)ImmunotherapyTomography X-Ray ComputedbusinessProgressive diseaseFollow-Up StudiesAcademic Radiology
researchProduct